The purpose of this study was to propose a verification method and results of intensity-modulated proton therapy (IMPT), using a commercially available heterogeneous phantom. We used a simple simulated head and neck and prostate phantom.
| INTRODUCTION
In recent years, proton beams have become widely used for the treatment of various types of cancer. Active scanning is one of the delivery techniques for proton therapy. 1 The active scanning method moves a spot along the longitudinal and horizontal axis and uses different energy beams to create three-dimensional dose distributions. There are two different delivery methods for scanning proton therapy; the first is single field uniform dose (SFUD) 2 and the second is intensity-modulated proton therapy (IMPT). 3, 4 IMPT is more flexible than SFUD and, in general, can deliver a more conformal prescribed dose to the target with lower dose to organs at risks (OARs). IMPT is more sensitive to the uncertainty due to the proton range and mechanical errors than SFUD because IMPT delivers a nonuniform dose distribution to each field. Since the total dose distributions of IMPT are created by summation of some nonuniform dose distributions, it can potentially cause unexpected dramatically hot or cold spots by the combination of inhomogeneity of the human body, machine variations, range uncertainty, and accuracy of the beam modeling or the dose calculation algorithm. 5, 6 From this perspective, accurate commissioning, quality assurance (QA)
including machine validations and verification of the treatment planning system are fundamental to implementing high-quality IMPT. Heterogeneous phantoms have been effectively used to evaluate the total dose including accuracy of dose calculation and machine variations, and to identify problems that are not revealed by the homogeneous phantom measurements. For this reason, anthropomorphic heterogeneous phantoms are used for the verification of intensity-modulated radiotherapy 7, 8 and also used with a thermoluminescent dosimeter (TLD) dosimeter and radiochromic film to verify scattering, pencil beam and uniform scanning plans. 9, 10 Furthermore, the results of patient-specific QA of IMPT in some sites using various techniques were excellent. [11] [12] [13] [14] [15] However, few studies have focused on the verification for IMPT using commercially available system, especially absolute dose measurement using heterogeneous phantom and ionization chamber. The paper by Taylor et al. 10 reported the summarization for clinical trial credentialing of scattered and scanning proton beam using TLD dosimeter, radiochromic film, absolute dose measurement using a solid phantom. 20 In this study, we obtained the fluence correction factor as the ratio of measured dose in the water and that in the soft-tissue phantom material at the same effective depths. Subsequently, an approximate linear formula was derived as the fluence correction factor. The fluence correction for bone phantom is not considered in this paper. The scanned field size was 10 × 10 cm 2 , and the energies and SOBPs used were adapted to each measurement depth. The scanning patterns and measurement depths are summarized in Table 1 . To measure at 3 cm depth, we used an energy absorber that had 4 cm water equivalent thickness because the minimum penetration depth of our system was 4 cm. The details on energy absorber will be mentioned in the next section.
2.B | Treatment planning and proton delivery system
The TPS used in this study was VQA (ver 3.0.1 Hitachi Ltd., Tokyo, Japan), a commercially available TPS in Japan. This is the first system that uses the TG model for the dose calculation. The TG model shows distinct difference with other low-dose kernel models in the high energy region where the influence of the secondary particles produced by nuclear interactions in water is increased. In the typical volumetric irradiation, the TG model reported better agreement to the measurement value especially small or large fields and narrow SOBP width condition. 21 The structures, mock clinical target volume (CTV) and
OARs of prostate and HN, and dose constraints were adopted from
AAPM Task Group-119 22 that has produced quantitative confidence limits as baseline expectation values for IMRT commissioning. We used the worst case optimization, 23 the parameters of which were 3 mm for each direction and 3.5% for range uncertainty. The scanning delivery system used in this study was installed in Nagoya Proton Therapy Center. The synchrotron can produce 95 proton beams energies having water penetration distances from 40 to 306 mm. The maximum spot size (1σ) in air at the isocenter plane is 13.8 mm, and the minimum is 4.7 mm. 24, 25 To irradiate shallow regions less than 40 mm, we used the energy absorber that had 40 mm water equivalent thickness. The energy absorber can be attached to the beam nozzle and can be used with patient-specific aperture. 26 The spot size of minimum range with energy absorber was 26.7 mm. In this study, we use energy absorber to measure fluence correction factor at 3 cm depth. The energies used in verification plan were from 84.7 to 187.7 MeV for HN planning and from 100.2 MeV to 205.9 MeV for prostate planning. In a clinical setting, we use two parallel-opposed SFUD fields for prostate treatment; however, the simulated prostate plan was created with a 4-fields IMPT plan in this study. The HN plan was created with five fields.
2.C | Experimental measurements
An ionization chamber (3D-PinPopint chamber, PTW30016) and a radiochromic film (Gafchromic EBT3 film, ISP) were used for absolute and dose distribution measurement. The absolute dose measurement involves uncertainties such as effective points of the ionization chamber, setup error, and variations of the mechanical isocenter of a gantry rotation. In the measurement of absolute dose for proton beam, the uncertainty of the effective point is particularly an F I G . 1. Measurement points and dose distributions of each field and accumulated dose of simulated prostate plan. Circled numbers shown in the accumulated image are measurement dose points. Measurement point 2 was the maximum dose point and overlapping in number 1.
important issue because proton dose distributions have a gradient to the depth direction unlike x-ray dose distributions. Hence, the effective measurement point of the cylindrical ionization chamber should be considered to each gantry angle and the dose uncertainty due to the effective point is not able to estimate by the total dose distribution. The effective measurement point of the cylindrical ionization chamber in proton therapy has been investigated in several studies, and was roughly 1 mm for the PTW 31016 chamber. [26] [27] [28] The uncertainty of the mechanical isocenter of gantry rotation of the our system has less than 1 mm accuracy. 29 In this report, we have dealt with the error of the measurement point up to 2 mm to the source direction and 1 mm to other directions for each gantry angle, and dose uncertainties were presumed from calculation results of each field dose of TPS. In the simulated prostate plan, the ionization chamber was located at the isocenter, near the rectum region and maximum dose point. In the simulated HN plan, the ionization chamber was located at the isocenter, near to OARs and hot spots. EBT3
films were cut to fit the RT-3000 phantom and inserted into the phantom on three planes. Consequently, the RT-3000 phantom required a phantom-specific HU-RSP conversion table especially for the bone phantom because the phantom was made from artificial materials. The uncertainty of the RSP for the RT-3000 phantom was estimated as 0.45% from the results of multiple measurements of the materials and this uncertainty was sufficiently small. Figure 3 shows the measured results for the fluence correction factor. We adopted a linear approximation formula method to correct measurement values by depth. These results closely resemble those of a previous study 20 that were obtained with a nonmodulated 191 MeV beam, a PMMA, and a Markus-type planeparallel ionization chamber. We assume that the dose distributions were formed by the convolution of nonmodulated proton beams, so the fluence scaling factor of our scanning method was closer to the nonmodulated result of the previous study. However, the when the using uniform phantom, the largest dose difference in the typical volumetric irradiation of our TPS is 1.3% at the shallow region of the small field. 21 In this study, the calculation dose error was assumed to increase because we use IMPT field and heterogeneous phantom. However, the dose differences of these error points were within 5%. Previous studies have reported that radiochromic film shows under-response of about 10% at the Bragg peak region and a variation in film sensitivity due to LET of 5% [30] [31] [32] [33] [34] ; therefore, results of this study showed sufficiently good. The reason for the good gamma pass rate and dose agreement within 5% were presumed to be that the average LET of IMPT HN plan was almost the same as the LET of the calibration depth.
| CONCLUSION
Herein, we reported dosimetric verification methods and results for the IMPT with new TG model-based TPS using a commercially available simple heterogeneous phantom, an ionization chamber, and radiochromic film. Considering various uncertainties, the measured and calculated doses showed good agreement. Our results demonstrated that heterogeneous phantoms are useful for verification of IMPT by using phantom-specific HU-RSP conversion tables. However, ionization chamber measurement is required to determine the effective measurement point for each field and to estimate the dose variation. The fluence correction by each depth for scanning proton beams is a simple method and results showed good accuracy. Nevertheless, fluence correction factor requires further investigation because that had up to 1.0% variance as shown in Fig. 4 . Heterogeneous phantoms can be effective for evaluating the total dose, including accuracy of dose calculation and machine variations, and can help to identify problems that are not revealed by homogeneous phantom measurements.
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